
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon's positive outlook is supported by its strategic positioning as a leading global late-stage contract research organization, particularly in a growing market characterized by increased pharmaceutical outsourcing and expanding R&D budgets. The successful acquisition of PRA has enhanced Icon's operational capabilities and allowed it to meet financial targets ahead of schedule, positioning the company well for future growth amid uncertain funding environments. Additionally, Icon's commitment to diversity and gender parity among leadership reflects a progressive company culture that may contribute to its competitive advantage in attracting talent and fostering innovation.
Bears say
Icon's stock outlook appears negative due to several fundamental concerns, including a reported book-to-bill ratio of 0.99 for a key competitor, Medpace, indicating demand challenges within the biotech-focused contract research organization sector. Furthermore, the anticipated earnings per share (EPS) for 2025 is projected to remain flat at the midpoints, highlighting stagnation amidst an environment of expected volatility and slower-than-anticipated recovery within the biotech industry. Additionally, a declining growth forecast, with an implied range of -2.8% to +4.5%, suggests ongoing revenue pressures that could lead to both reduced earnings and potential multiple compression moving forward.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares